Abstract：
UNASSIGNED: The long-term estimated risk of development of cataracts among pediatric patients with uveitis is not clear.
UNASSIGNED: To describe factors associated with the development of cataracts among pediatric patients with uveitis.
UNASSIGNED: This cohort study used the international TriNetX database to enroll pediatric patients with and without uveitis from January 1, 2002, to December 31, 2022. The nonuveitis cohort consisted of randomly selected control patients matched by age, sex, race and ethnicity, and specific comorbidities.
UNASSIGNED: Diagnosis of uveitis, identified using diagnostic codes.
UNASSIGNED: The primary outcome was the risk of developing cataracts among the uveitis group compared with the nonuveitis comparison group, with hazard ratios (HRs) and 95% CIs reported.
UNASSIGNED: A total of 22 687 pediatric patients with uveitis (mean [SD] age, 10.3 [5.6] years; 54.2% male) and 22 687 comparators without uveitis (mean [SD] age, 10.3 [5.6] years; 54.5% male) were enrolled in the study. The risk of cataracts was increased among pediatric patients with uveitis up to a follow-up duration of 20 years (HR, 17.17; 95%CI, 12.90-22.80) from the index date. Subgroup analyses revealed an elevated cataract risk across age groups: 0 to 6 years (HR, 19.09; 95% CI, 10.10-36.00), 7 to 12 years (HR, 27.16; 95% CI, 15.59-47.20), and 13 to 18 years (HR, 13.39; 95% CI, 8.84-20.30); both female sex (HR, 13.76; 95% CI, 9.60-19.71) and male sex (HR, 11.97; 95% CI, 8.47-16.91); and Asian (HR, 13.80; 95% CI, 3.28-58.07), Black or African American (HR, 10.41; 95% CI, 5.60-19.36), and White (HR, 15.82; 95% CI, 11.05-22.60) race. Furthermore, increased cataract risks were also observed among those with and without a history of immunosuppressive agents (with: HR, 26.52 [95% CI, 16.75-41.90]; without: HR, 17.69 [95% CI: 11.39-27.40]), a history of steroid eye drop use (with: HR, 29.51 [95% CI, 14.56-59.70]; without: HR, 16.49 [95% CI, 11.92-22.70]), and a history of intraocular procedures (with: HR, 11.07 [95%CI, 4.42-27.71]; without: HR, 14.49 [95% CI, 10.11-20.70]).
UNASSIGNED: In this cohort study of pediatric patients with uveitis, an elevated risk of cataracts following a uveitis diagnosis was found compared with pediatric patients without uveitis. The findings suggest that pediatric patients with uveitis should be monitored for cataract development.
UNASSIGNED: To describe factors associated with the development of cataracts among pediatric patients with uveitis.
UNASSIGNED: This cohort study used the international TriNetX database to enroll pediatric patients with and without uveitis from January 1, 2002, to December 31, 2022. The nonuveitis cohort consisted of randomly selected control patients matched by age, sex, race and ethnicity, and specific comorbidities.
UNASSIGNED: Diagnosis of uveitis, identified using diagnostic codes.
UNASSIGNED: The primary outcome was the risk of developing cataracts among the uveitis group compared with the nonuveitis comparison group, with hazard ratios (HRs) and 95% CIs reported.
UNASSIGNED: A total of 22 687 pediatric patients with uveitis (mean [SD] age, 10.3 [5.6] years; 54.2% male) and 22 687 comparators without uveitis (mean [SD] age, 10.3 [5.6] years; 54.5% male) were enrolled in the study. The risk of cataracts was increased among pediatric patients with uveitis up to a follow-up duration of 20 years (HR, 17.17; 95%CI, 12.90-22.80) from the index date. Subgroup analyses revealed an elevated cataract risk across age groups: 0 to 6 years (HR, 19.09; 95% CI, 10.10-36.00), 7 to 12 years (HR, 27.16; 95% CI, 15.59-47.20), and 13 to 18 years (HR, 13.39; 95% CI, 8.84-20.30); both female sex (HR, 13.76; 95% CI, 9.60-19.71) and male sex (HR, 11.97; 95% CI, 8.47-16.91); and Asian (HR, 13.80; 95% CI, 3.28-58.07), Black or African American (HR, 10.41; 95% CI, 5.60-19.36), and White (HR, 15.82; 95% CI, 11.05-22.60) race. Furthermore, increased cataract risks were also observed among those with and without a history of immunosuppressive agents (with: HR, 26.52 [95% CI, 16.75-41.90]; without: HR, 17.69 [95% CI: 11.39-27.40]), a history of steroid eye drop use (with: HR, 29.51 [95% CI, 14.56-59.70]; without: HR, 16.49 [95% CI, 11.92-22.70]), and a history of intraocular procedures (with: HR, 11.07 [95%CI, 4.42-27.71]; without: HR, 14.49 [95% CI, 10.11-20.70]).
UNASSIGNED: In this cohort study of pediatric patients with uveitis, an elevated risk of cataracts following a uveitis diagnosis was found compared with pediatric patients without uveitis. The findings suggest that pediatric patients with uveitis should be monitored for cataract development.
摘要：
■葡萄膜炎患儿发生白内障的长期估计风险尚不清楚。
■描述与葡萄膜炎患儿白内障发展相关的因素。
■这项队列研究使用国际TriNetX数据库，从2002年1月1日至2022年12月31日招募有和没有葡萄膜炎的儿科患者。非葡萄膜炎队列由随机选择的对照患者组成，这些患者的年龄相匹配，性别,种族和民族,和特定的合并症。
■葡萄膜炎的诊断，使用诊断代码识别。
■主要结果是葡萄膜炎组与非葡萄膜炎对照组相比患白内障的风险，报告了风险比（HR）和95%CI。
■共有22687例小儿葡萄膜炎患者（平均[SD]年龄，10.3[5.6]岁；54.2%男性)和22687名没有葡萄膜炎的对比者(平均[SD]年龄，10.3[5.6]岁；54.5%男性）参加了研究。在患有葡萄膜炎的儿科患者中，白内障的风险增加了，随访时间长达20年（HR，17.17；95CI，12.90-22.80）自指数日起。亚组分析显示，各年龄组的白内障风险升高：0至6岁(HR，19.09；95%CI，10.10-36.00），7至12年(HR，27.16；95%CI，15.59-47.20），和13到18岁(人力资源，13.39；95%CI，8.84-20.30）；女性（HR，13.76；95%CI，9.60-19.71）和男性（HR，11.97；95%CI，8.47-16.91）；亚洲（HR，13.80；95%CI，3.28-58.07），黑人或非裔美国人(HR，10.41；95%CI，5.60-19.36），和怀特（HR，15.82；95%CI，11.05-22.60）种族。此外，在有和没有免疫抑制剂病史的人群中也观察到白内障风险增加(与：HR，26.52[95%CI，16.75-41.90]；无：HR，17.69[95%CI：11.39-27.40])，类固醇滴眼液使用史(与：HR，29.51[95%CI，14.56-59.70]；无：HR，16.49[95%CI，11.92-22.70])，和眼内手术史（与：HR，11.07[95CI，4.42-27.71]；无：HR，14.49[95%CI，10.11-20.70]）。
■在这项针对小儿葡萄膜炎患者的队列研究中，与没有葡萄膜炎的儿科患者相比，葡萄膜炎诊断后白内障的风险升高。研究结果表明，应监测患有葡萄膜炎的小儿患者的白内障发展。
■描述与葡萄膜炎患儿白内障发展相关的因素。
■这项队列研究使用国际TriNetX数据库，从2002年1月1日至2022年12月31日招募有和没有葡萄膜炎的儿科患者。非葡萄膜炎队列由随机选择的对照患者组成，这些患者的年龄相匹配，性别,种族和民族,和特定的合并症。
■葡萄膜炎的诊断，使用诊断代码识别。
■主要结果是葡萄膜炎组与非葡萄膜炎对照组相比患白内障的风险，报告了风险比（HR）和95%CI。
■共有22687例小儿葡萄膜炎患者（平均[SD]年龄，10.3[5.6]岁；54.2%男性)和22687名没有葡萄膜炎的对比者(平均[SD]年龄，10.3[5.6]岁；54.5%男性）参加了研究。在患有葡萄膜炎的儿科患者中，白内障的风险增加了，随访时间长达20年（HR，17.17；95CI，12.90-22.80）自指数日起。亚组分析显示，各年龄组的白内障风险升高：0至6岁(HR，19.09；95%CI，10.10-36.00），7至12年(HR，27.16；95%CI，15.59-47.20），和13到18岁(人力资源，13.39；95%CI，8.84-20.30）；女性（HR，13.76；95%CI，9.60-19.71）和男性（HR，11.97；95%CI，8.47-16.91）；亚洲（HR，13.80；95%CI，3.28-58.07），黑人或非裔美国人(HR，10.41；95%CI，5.60-19.36），和怀特（HR，15.82；95%CI，11.05-22.60）种族。此外，在有和没有免疫抑制剂病史的人群中也观察到白内障风险增加(与：HR，26.52[95%CI，16.75-41.90]；无：HR，17.69[95%CI：11.39-27.40])，类固醇滴眼液使用史(与：HR，29.51[95%CI，14.56-59.70]；无：HR，16.49[95%CI，11.92-22.70])，和眼内手术史（与：HR，11.07[95CI，4.42-27.71]；无：HR，14.49[95%CI，10.11-20.70]）。
■在这项针对小儿葡萄膜炎患者的队列研究中，与没有葡萄膜炎的儿科患者相比，葡萄膜炎诊断后白内障的风险升高。研究结果表明，应监测患有葡萄膜炎的小儿患者的白内障发展。
